China News Service, July 15th, according to foreign media reports, on the 14th local time, the US biotechnology company Modena said that the company's new crown vaccine will enter the final stage of human trials on July 27th. According to reports, Modena is the first company in the United States to enter the final phase of the new crown vaccine trial.
According to reports, the trial will include 30,000 participants, half of whom will receive a 100-microgram dose of vaccine and the other half will receive a placebo. The trial may continue until October 27.
The report said that the research results published in the "New England Journal of Medicine" on July 14th showed that the results of the previous stage of the Modena New Crown vaccine showed that 45 participants had produced antibodies to the virus in the body.
The report pointed out that the Modena new crown vaccine mainly includes a genetic material called mRNA, which can give instructions to cells to produce antigens that include immunity to the new crown virus. The advantage of this technology is that it does not require the production of viral proteins in the laboratory, which saves months of standardized process time and helps increase the speed of mass production.
Modena said that if everything goes well in future research, "the company is expected to provide about 500 million doses of vaccines every year starting from 2021, and even up to 1 billion doses."
According to WHO data, there are currently more than 100 new crown vaccines under development worldwide. But scientists warn that the first vaccines on the market are not necessarily the most effective or safest.